Minakem Minakem

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"Touchlight","sponsor":"Cancer Research","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Cancer Research UK, University of Southampton and Touchlight Genetics Partner to Develop Head and Neck Cancer Vaccine","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"UNITED KINGDOM","productType":"Vaccine","productStatus":"New Molecular Entity","date":"July 2020","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical"},{"orgOrder":0,"company":"Touchlight","sponsor":"Versameb","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Touchlight and Versameb Announce GMP Manufacturing Supply Agreement","therapeuticArea":"Urology","highestDevelopmentStatus":"Preclinical","country":"UNITED KINGDOM","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2022","url1":"","url2":"","graph1":"Urology","graph2":"Preclinical"},{"orgOrder":0,"company":"Touchlight","sponsor":"Pfizer Inc","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Touchlight Signs Patent License Agreement with Pfizer for The Use of dbDNA For the Manufacture of mRNA-Based Vaccines, Therapeutics and Gene Therapies","therapeuticArea":"Technology","highestDevelopmentStatus":"Undisclosed","country":"UNITED KINGDOM","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2022","url1":"","url2":"","graph1":"Technology","graph2":"Undisclosed"},{"orgOrder":0,"company":"Touchlight","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Touchlight Announces Development of A Vaccine Against COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Discovery","country":"UNITED KINGDOM","productType":"Vaccine","productStatus":"New Molecular Entity","date":"August 2020","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Discovery"},{"orgOrder":0,"company":"Touchlight","sponsor":"Lonza Capsugel","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Lonza and Touchlight Collaborate on End-To-End mRNA Offering","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"UNITED KINGDOM","productType":"Vaccine","productStatus":"New Molecular Entity","date":"September 2022","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical"},{"orgOrder":0,"company":"Touchlight","sponsor":"Voyager Therapeutics, Inc","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Touchlight Signs License Agreement With Voyager for Use of Touchlight\u2019s DNA Technology in Voyager\u2019s Capsid Discovery Platform","therapeuticArea":"Technology","highestDevelopmentStatus":"Discovery Platform","country":"UNITED KINGDOM","productType":"Undisclosed","productStatus":"Undisclosed","date":"November 2022","url1":"","url2":"","graph1":"Technology","graph2":"Discovery Platform"},{"orgOrder":0,"company":"Touchlight","sponsor":"Odimma Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Touchlight and Odimma Therapeutics Announce Clinical Material Supply Agreement to Develop Personalised Cancer Therapy Utilising Doggybone DNA","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","productStatus":"Undisclosed","date":"December 2022","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery"},{"orgOrder":0,"company":"Touchlight","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Touchlight Announces First FDA Clearance of an IND Utilising Doggybone DNA","therapeuticArea":"Technology","highestDevelopmentStatus":"IND Enabling","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"February 2023","url1":"","url2":"","graph1":"Technology","graph2":"IND Enabling"}]

    Find Clinical Drug Pipeline Developments & Deals by Touchlight

    Menu

    Touchlight

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    SERVICES

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              Touchlight

              Contact Supplier
              • Development Update
              Virtual BoothTouchlight, The Making of DNA
              Contact Supplier Contact Supplier
              Flag United Kingdom
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Touchlight Announces First FDA Clearance of an IND Utilising Doggybone DNA

              Details:

              dbDNA technology produces a minimal, linear, double stranded, covalently closed DNA vector through an enzymatic manufacturing process. dbDNA will be used as an in vitro transcription template for mRNA production in the manufacturing of a cell therapy product.

              Lead Product(s): Undisclosed

              Therapeutic Area: Technology Product Name: Undisclosed

              Highest Development Status: IND Enabling Product Type: Cell and Gene therapy

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable February 28, 2023

              Touchlight CB

              12th Austrian Peptide Symposium

              Not Confirmed

              envelop Contact Supplier

              Touchlight

              Contact Supplier
              • Deals
              Virtual BoothTouchlight, The Making of DNA
              Contact Supplier Contact Supplier
              Flag United Kingdom
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Touchlight and Odimma Therapeutics Announce Clinical Material Supply Agreement to Develop Personalised Cancer Therapy Utilising Doggybone DNA

              Details:

              Odimma will gain access to Touchlight’s proprietary doggybone DNA (dbDNA™) vector technology, providing them with a clinical supply of personalised dbDNA™, to support and underpin the development of their candidate immunotherapy cancer treatment.

              Lead Product(s): Undisclosed

              Therapeutic Area: Oncology Product Name: Undisclosed

              Highest Development Status: Discovery Product Type: Cell and Gene therapy

              Partner/Sponsor/Collaborator: Odimma Therapeutics

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Agreement December 07, 2022

              Touchlight CB

              12th Austrian Peptide Symposium

              Not Confirmed

              envelop Contact Supplier

              Touchlight

              Contact Supplier
              • Deals
              Virtual BoothTouchlight, The Making of DNA
              Contact Supplier Contact Supplier
              Flag United Kingdom
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Touchlight Signs License Agreement With Voyager for Use of Touchlight’s DNA Technology in Voyager’s Capsid Discovery Platform

              Details:

              Under the license agreement, Voyager gains rights to Touchlight’s DNA technology for use in the creation of novel capsids with the potential to power programs in Voyager’s pipeline and supporting Voyager alliances with leading biopharma partners.

              Lead Product(s): Undisclosed

              Therapeutic Area: Technology Product Name: Undisclosed

              Highest Development Status: Discovery Platform Product Type: Undisclosed

              Partner/Sponsor/Collaborator: Voyager Therapeutics, Inc

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Licensing Agreement November 15, 2022

              Touchlight CB

              12th Austrian Peptide Symposium

              Not Confirmed

              envelop Contact Supplier

              Touchlight

              Contact Supplier
              • Deals
              Virtual BoothTouchlight, The Making of DNA
              Contact Supplier Contact Supplier
              Flag United Kingdom
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Lonza and Touchlight Collaborate on End-To-End mRNA Offering

              Details:

              Under the terms of the agreement, Lonza can now provide its customers with seamless access to Touchlight’s enzymatic DNA technology; a linear, covalently closed DNA vector, produced using an enzymatic manufacturing process.

              Lead Product(s): mRNA-based Vaccine

              Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

              Highest Development Status: Preclinical Product Type: Vaccine

              Recipient: Lonza Capsugel

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Collaboration September 06, 2022

              Touchlight CB

              12th Austrian Peptide Symposium

              Not Confirmed

              envelop Contact Supplier

              Touchlight

              Contact Supplier
              • Deals
              Virtual BoothTouchlight, The Making of DNA
              Contact Supplier Contact Supplier
              Flag United Kingdom
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Touchlight Signs Patent License Agreement with Pfizer for The Use of dbDNA For the Manufacture of mRNA-Based Vaccines, Therapeutics and Gene Therapies

              Details:

              Under the license agreement, Pfizer gains rights to Touchlight’s enzymatic doggybone DNA (dbDNA™) patent portfolio for worldwide use in Pfizer’s manufacture and commercialisation of its messenger RNA-based vaccines, therapeutics and gene therapies.

              Lead Product(s): mRNA-based Vaccine

              Therapeutic Area: Technology Product Name: Undisclosed

              Highest Development Status: Undisclosed Product Type: Large molecule

              Partner/Sponsor/Collaborator: Pfizer Inc

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Licensing Agreement July 06, 2022

              Touchlight CB

              12th Austrian Peptide Symposium

              Not Confirmed

              envelop Contact Supplier

              Touchlight

              Contact Supplier
              • Deals
              Virtual BoothTouchlight, The Making of DNA
              Contact Supplier Contact Supplier
              Flag United Kingdom
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Touchlight and Versameb Announce GMP Manufacturing Supply Agreement

              Details:

              The agreement enables Versameb to use Touchlight’s proprietary doggybone DNA (dbDNA™) vector technology to support the development of novel mRNA-based therapeutics, including VMB-100, addressing unmet needs in urology and oncology.

              Lead Product(s): VMB-100

              Therapeutic Area: Urology Product Name: VMB-100

              Highest Development Status: Preclinical Product Type: Large molecule

              Partner/Sponsor/Collaborator: Versameb

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Agreement March 01, 2022

              Touchlight CB

              12th Austrian Peptide Symposium

              Not Confirmed

              envelop Contact Supplier

              Touchlight

              Contact Supplier
              • Development Update
              Virtual BoothTouchlight, The Making of DNA
              Contact Supplier Contact Supplier
              Flag United Kingdom
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Touchlight Announces Development of A Vaccine Against COVID-19

              Details:

              The vaccine targets multiple viral antigens with the aim of generating an antibody and T-cell based immune response, whose breadth more closely mimics that of convalescent patients.

              Lead Product(s): Undisclosed

              Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

              Highest Development Status: Discovery Product Type: Vaccine

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable August 21, 2020

              Touchlight CB

              12th Austrian Peptide Symposium

              Not Confirmed

              envelop Contact Supplier

              Touchlight

              Contact Supplier
              • Deals
              Virtual BoothTouchlight, The Making of DNA
              Contact Supplier Contact Supplier
              Flag United Kingdom
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Cancer Research UK, University of Southampton and Touchlight Genetics Partner to Develop Head and Neck Cancer Vaccine

              Details:

              The new clinical development partnership aims at progressing a therapeutic DNA vaccine, TGL-100, into an early phase clinical trial targeting head and neck squamous cell carcinoma (HNSCC).

              Lead Product(s): TGL-100

              Therapeutic Area: Oncology Product Name: TGL-100

              Highest Development Status: Preclinical Product Type: Vaccine

              Recipient: Cancer Research

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Partnership July 29, 2020

              Touchlight CB

              12th Austrian Peptide Symposium

              Not Confirmed

              envelop Contact Supplier
              Touchlight RMU
              Send me more info on How To Grow My Business Digitally?
              Post Enquiry
              POST ENQUIRY